The conversion of xanthine dehydrogenase to xanthine oxidase and the role of the enzyme in reperfusion injury
- PMID: 7798166
- DOI: 10.1093/oxfordjournals.jbchem.a124480
The conversion of xanthine dehydrogenase to xanthine oxidase and the role of the enzyme in reperfusion injury
Abstract
Although mammalian xanthine oxidase exists originally as a dehydrogenase form in freshly prepared samples, it is converted to an oxidase form during purification, either irreversibly by proteolysis or reversibly by sulfhydryl oxidation of the protein molecule. However, avoiding proteolysis the mammalian enzyme can be purified as an interconvertible form and thus can be used to compare directly the properties of xanthine dehydrogenase and the oxidase derived from the same enzyme molecule. The cDNAs encoding the enzyme have been cloned from several sources, and structural information is becoming available. The most significant difference between the two forms is the protein conformation around FAD, which changes the redox potential of the flavin and the reactivity of FAD with the electron acceptors, NAD and molecular oxygen. The flavin semiquinone is thermodynamically stable in xanthine dehydrogenase, but is unstable in xanthine oxidase. Detailed analyses by stopped-flow techniques suggest that the flavin semiquinone reacts with oxygen to form superoxide anion while the fully reduced flavin reacts to form hydrogen peroxide. Although xanthine dehydrogenase can produce greater amounts of superoxide anion than xanthine oxidase during xanthine-oxygen turnover, it seems to be physiologically insignificant because NAD inhibits almost completely the formation of superoxide anion. Although the involvement of this enzyme in reperfusion injury has been proposed, this seems to be more complex than originally envisaged and still remains to be established.
Similar articles
-
The role of the [2Fe-2s] cluster centers in xanthine oxidoreductase.J Inorg Biochem. 2000 Nov;82(1-4):43-9. doi: 10.1016/s0162-0134(00)00165-3. J Inorg Biochem. 2000. PMID: 11132637 Review.
-
Flavoprotein structure and mechanism. 4. Xanthine oxidase and xanthine dehydrogenase.FASEB J. 1995 Aug;9(11):995-1003. FASEB J. 1995. PMID: 7649415 Review.
-
Mammalian xanthine oxidoreductase - mechanism of transition from xanthine dehydrogenase to xanthine oxidase.FEBS J. 2008 Jul;275(13):3278-89. doi: 10.1111/j.1742-4658.2008.06489.x. Epub 2008 May 30. FEBS J. 2008. PMID: 18513323 Review.
-
Kinetic comparison of reduction and intramolecular electron transfer in milk xanthine oxidase and chicken liver xanthine dehydrogenase by laser flash photolysis.Biochemistry. 1991 Jun 18;30(24):5912-7. doi: 10.1021/bi00238a015. Biochemistry. 1991. PMID: 2043632
-
The C-terminal peptide plays a role in the formation of an intermediate form during the transition between xanthine dehydrogenase and xanthine oxidase.FEBS J. 2015 Aug;282(16):3075-90. doi: 10.1111/febs.13277. Epub 2015 Apr 13. FEBS J. 2015. PMID: 25817260 Free PMC article.
Cited by
-
Plasma Xanthine Oxidoreductase Activity Is Associated with a High Risk of Cardiovascular Disease in a General Japanese Population.Int J Environ Res Public Health. 2021 Feb 16;18(4):1894. doi: 10.3390/ijerph18041894. Int J Environ Res Public Health. 2021. PMID: 33669298 Free PMC article.
-
Reperfusion injury and reactive oxygen species: The evolution of a concept.Redox Biol. 2015 Dec;6:524-551. doi: 10.1016/j.redox.2015.08.020. Epub 2015 Oct 8. Redox Biol. 2015. PMID: 26484802 Free PMC article. Review.
-
Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study.Biomedicines. 2023 Mar 1;11(3):754. doi: 10.3390/biomedicines11030754. Biomedicines. 2023. PMID: 36979733 Free PMC article. Review.
-
Review 2: Primary graft dysfunction after lung transplant-pathophysiology, clinical considerations and therapeutic targets.J Anesth. 2020 Oct;34(5):729-740. doi: 10.1007/s00540-020-02823-6. Epub 2020 Jul 20. J Anesth. 2020. PMID: 32691226 Free PMC article. Review.
-
Relationship between Xanthine Oxidoreductase Redox and Oxidative Stress among Chronic Kidney Disease Patients.Oxid Med Cell Longev. 2018 Jul 8;2018:9714710. doi: 10.1155/2018/9714710. eCollection 2018. Oxid Med Cell Longev. 2018. PMID: 30116501 Free PMC article.